Skip to main content
Erschienen in: Endocrine 2/2016

17.05.2016 | Original Article

Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine

verfasst von: Lawrence Kashat, Steven Orlov, David Orlov, Jasmeet Assi, Farnaz Salari, Paul G. Walfish

Erschienen in: Endocrine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to determine the natural temporal trends of serial thyroglobulin (Tg) among low/intermediate-risk PTC patients not receiving radioactive iodine (RAI) using TSH-stimulated Tg (Stim-Tg) and unstimulated highly sensitive Tg (u-hsTg). We prospectively analyzed serial Stim-Tg measurements after total thyroidectomy ± therapeutic central neck dissection among 121 consecutive low/intermediate-risk PTC patients who did not receive RAI, of whom 104 also had serial u-hsTg measurements available. Median follow-up was 6.5 years with Stim-Tg measurements commencing 3 months after surgery and u-hsTg commencing 1.8 years after surgery (when the assay became available). TSH stimulation was performed with 9-day T3 withdrawal, 22-day T4 withdrawal, or using recombinant human TSH (rhTSH). To account for within-patient correlations of repeated Tg measurements, temporal trends in Stim-Tg and u-hsTg were assessed using Generalized Estimating Equations. Stim-Tg models were adjusted for the method of TSH stimulation, whereas the u-hsTg models were adjusted for concurrent TSH level. Linear regression modeling was used to assess the trend in serial Stim-Tg and u-hsTg measurements as a function time from time of surgery throughout the duration of follow-up. The main outcome measured was the change in u-hsTg and Stim-Tg measurements over time. A total of 337 Stim-Tg (2.8/patient) and 602 u-hsTg (5.8/patient) measurements were analyzed. Among the 337 Stim-Tg measurements, Stim-Tg was assessed using rhTSH in 202 (60 %), T4 withdrawal in 41 (12 %), and T3 withdrawal in 94 (28 %) measurements. The overall mean ± 1SD for Stim-Tg and u-hsTg measured was 1.0 ± 1.2 and 0.2 ± 0.1 μg/L, respectively. When adjusted for method of TSH stimulation, serial Stim-Tg measurements did not significantly change over time (all p = NS). The estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were 0.01, −0.08, and 0.04 μg/L, respectively. Upon exclusion of 73 patients with an initial undetectable Stim-Tg (n = 48), serial Stim-Tg measurements did not change significantly over time (all p = NS). For these patients, the estimated changes in Stim-Tg per year for rhTSH, T4 withdrawal, and T3 withdrawal were −0.09, −0.10, and 0.01 μg/L, respectively. Serial u-hsTg measurements did not significantly change over time after adjusting for TSH level (p = NS). The estimated change in u-hsTg per year was −0.003 μg/L. No patients had any clinical or imaging evidence of a recurrence during the duration of their follow-up. Among low/intermediate-risk PTC patients not treated with RAI, serial post-surgical Stim-Tg and u-hsTg measurements do not change significantly over a median follow-up of 6.5 years.
Literatur
2.
Zurück zum Zitat A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668–3676 (2004). doi:10.1210/jc.2003-031167 CrossRefPubMed A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89(8), 3668–3676 (2004). doi:10.​1210/​jc.​2003-031167 CrossRefPubMed
3.
Zurück zum Zitat A. Vaisman, S. Orlov, J. Yip, C. Hu, T. Lim, M. Dowar, J.L. Freeman, P.G. Walfish, Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32(6), 689–698 (2010). doi:10.1002/hed.21371 PubMed A. Vaisman, S. Orlov, J. Yip, C. Hu, T. Lim, M. Dowar, J.L. Freeman, P.G. Walfish, Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32(6), 689–698 (2010). doi:10.​1002/​hed.​21371 PubMed
4.
Zurück zum Zitat S. Orlov, F. Salari, L. Kashat, J.L. Freeman, A. Vescan, I.J. Witterick, P.G. Walfish, Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine 50(1), 130–137 (2015). doi:10.1007/s12020-015-0575-0 CrossRefPubMed S. Orlov, F. Salari, L. Kashat, J.L. Freeman, A. Vescan, I.J. Witterick, P.G. Walfish, Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine 50(1), 130–137 (2015). doi:10.​1007/​s12020-015-0575-0 CrossRefPubMed
5.
Zurück zum Zitat R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22(8), 778–783 (2012). doi:10.1089/thy.2011.0522 CrossRefPubMed R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22(8), 778–783 (2012). doi:10.​1089/​thy.​2011.​0522 CrossRefPubMed
6.
Zurück zum Zitat C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante, D. Meringolo, M. Ferdeghini, S. Tumino, L. Lamartina, A. Paciaroni, M. Massa, L. Giacomelli, G. Ronga, S. Filetti, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97(8), 2748–2753 (2012). doi:10.1210/jc.2012-1123 CrossRefPubMed C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani, G. Costante, D. Meringolo, M. Ferdeghini, S. Tumino, L. Lamartina, A. Paciaroni, M. Massa, L. Giacomelli, G. Ronga, S. Filetti, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J. Clin. Endocrinol. Metab. 97(8), 2748–2753 (2012). doi:10.​1210/​jc.​2012-1123 CrossRefPubMed
7.
Zurück zum Zitat T.E. Angell, C.A. Spencer, B.D. Rubino, J.T. Nicoloff, J.S. LoPresti, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 24(7), 1127–1133 (2014). doi:10.1089/thy.2013.0691 CrossRefPubMed T.E. Angell, C.A. Spencer, B.D. Rubino, J.T. Nicoloff, J.S. LoPresti, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid 24(7), 1127–1133 (2014). doi:10.​1089/​thy.​2013.​0691 CrossRefPubMed
8.
Zurück zum Zitat C. Spencer, J. LoPresti, S. Fatemi, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 394–404 (2014). doi:10.1097/med.0000000000000092 CrossRefPubMedPubMedCentral C. Spencer, J. LoPresti, S. Fatemi, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 394–404 (2014). doi:10.​1097/​med.​0000000000000092​ CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat S. Orlov, D. Orlov, M. Shaytzag, M. Dowar, V. Tabatabaie, P. Dwek, J. Yip, C. Hu, J.L. Freeman, P.G. Walfish, Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6), 782–788 (2009). doi:10.1002/hed.21020 CrossRefPubMed S. Orlov, D. Orlov, M. Shaytzag, M. Dowar, V. Tabatabaie, P. Dwek, J. Yip, C. Hu, J.L. Freeman, P.G. Walfish, Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31(6), 782–788 (2009). doi:10.​1002/​hed.​21020 CrossRefPubMed
10.
Zurück zum Zitat D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009). doi:10.1089/thy.2009.0110 CrossRefPubMed D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009). doi:10.​1089/​thy.​2009.​0110 CrossRefPubMed
11.
Zurück zum Zitat A. Golger, T.R. Fridman, S. Eski, I.J. Witterick, J.L. Freeman, P.G. Walfish, Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest. 26(10), 1023–1031 (2003)CrossRefPubMed A. Golger, T.R. Fridman, S. Eski, I.J. Witterick, J.L. Freeman, P.G. Walfish, Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest. 26(10), 1023–1031 (2003)CrossRefPubMed
13.
Zurück zum Zitat A.E. Hubbard, J. Ahern, N.L. Fleischer, M. Van der Laan, S.A. Lippman, N. Jewell, T. Bruckner, W.A. Satariano, To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology 21(4), 467–474 (2010). doi:10.1097/EDE.0b013e3181caeb90 CrossRefPubMed A.E. Hubbard, J. Ahern, N.L. Fleischer, M. Van der Laan, S.A. Lippman, N. Jewell, T. Bruckner, W.A. Satariano, To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology 21(4), 467–474 (2010). doi:10.​1097/​EDE.​0b013e3181caeb90​ CrossRefPubMed
14.
Zurück zum Zitat C.A. Spencer, L.M. Bergoglio, M. Kazarosyan, S. Fatemi, J.S. LoPresti, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90(10), 5566–5575 (2005). doi:10.1210/jc.2005-0671 CrossRefPubMed C.A. Spencer, L.M. Bergoglio, M. Kazarosyan, S. Fatemi, J.S. LoPresti, Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 90(10), 5566–5575 (2005). doi:10.​1210/​jc.​2005-0671 CrossRefPubMed
15.
Zurück zum Zitat A. Algeciras-Schimnich, M.A. Lasho, K.M. Ness, L.A. Cheryk, S.K. Grebe, The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 21(7), 813–814 (2011). doi:10.1089/thy.2011.0158 CrossRefPubMedPubMedCentral A. Algeciras-Schimnich, M.A. Lasho, K.M. Ness, L.A. Cheryk, S.K. Grebe, The Roche Elecsys and Siemens-Centaur thyroglobulin autoantibody assays show comparable clinical performance to the recently unavailable Beckman-Coulter access thyroglobulin autoantibody assay in identifying samples with potentially false-low thyroglobulin measurements due to thyroglobulin autoantibody interference. Thyroid 21(7), 813–814 (2011). doi:10.​1089/​thy.​2011.​0158 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat S. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene (eds.), A.T.: AJCC Cancer Staging Manual, 7 ed (Springer, New York, 2010) S. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene (eds.), A.T.: AJCC Cancer Staging Manual, 7 ed (Springer, New York, 2010)
17.
Zurück zum Zitat C. Nascimento, I. Borget, F. Troalen, A. Al Ghuzlan, D. Deandreis, D. Hartl, J. Lumbroso, C.N. Chougnet, E. Baudin, M. Schlumberger, S. Leboulleux, Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169(5), 689–693 (2013). doi:10.1530/eje-13-0386 CrossRefPubMed C. Nascimento, I. Borget, F. Troalen, A. Al Ghuzlan, D. Deandreis, D. Hartl, J. Lumbroso, C.N. Chougnet, E. Baudin, M. Schlumberger, S. Leboulleux, Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169(5), 689–693 (2013). doi:10.​1530/​eje-13-0386 CrossRefPubMed
18.
Zurück zum Zitat P.W. Rosario, G.F. Mourao, T.L. Siman, M.R. Calsolari, Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: a prospective study. Thyroid 25(7), 769–775 (2015). doi:10.1089/thy.2014.0496 CrossRefPubMed P.W. Rosario, G.F. Mourao, T.L. Siman, M.R. Calsolari, Serum thyroglobulin measured with a second-generation assay in patients undergoing total thyroidectomy without radioiodine remnant ablation: a prospective study. Thyroid 25(7), 769–775 (2015). doi:10.​1089/​thy.​2014.​0496 CrossRefPubMed
19.
Zurück zum Zitat P.W. Rosario, A.F. MineiroFilho, B.S. Prates, L.C. Silva, M.R. Calsolari, Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11), 1140–1143 (2012). doi:10.1089/thy.2012.0190 CrossRefPubMed P.W. Rosario, A.F. MineiroFilho, B.S. Prates, L.C. Silva, M.R. Calsolari, Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11), 1140–1143 (2012). doi:10.​1089/​thy.​2012.​0190 CrossRefPubMed
Metadaten
Titel
Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine
verfasst von
Lawrence Kashat
Steven Orlov
David Orlov
Jasmeet Assi
Farnaz Salari
Paul G. Walfish
Publikationsdatum
17.05.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0989-3

Weitere Artikel der Ausgabe 2/2016

Endocrine 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.